Mn‐Anti‐CTLA4‐CREKA‐Sericin Nanotheragnostics for Enhanced Magnetic Resonance Imaging and Tumor Immunotherapy
Zixuan Huang,Yejing Wang,Can Su,Wanting Li,Min Wu,Wuling Li,Jun Wu,Qingyou Xia,Huawei He
DOI: https://doi.org/10.1002/smll.202306912
IF: 13.3
2023-11-28
Small
Abstract:A multi‐functional theranostic nanosphere MCCS has been developed by covalently assembling sericin with Mn2+, CREKA, and aCTLA‐4. MCCS not only actively targets tumors to enhance MRI, but also activates the cGAS‐STING pathway, stimulates effector T cell proliferation, and reduces Treg cell number, increases IFN‐γ and granzyme secretion, raises ROS levels, thus efficiently killing tumors with little adverse effects. The integration of magnetic resonance imaging (MRI), cGAS‐STING, and anti‐CTLA‐4 (aCTLA‐4) based immunotherapy offers new opportunities for tumor precision therapy. However, the precise delivery of aCTLA‐4 and manganese (Mn), an activator of cGAS, to tumors remains a major challenge for enhanced MRI and active immunotherapy. Herein, a theragnostic nanosphere Mn‐CREKA‐aCTLA‐4‐SS (MCCS) is prepared by covalently assembling Mn2+, silk sericin (SS), pentapeptide CREKA, and aCTLA‐4. MCCS are stable with an average size of 160 nm and is almost negatively charged or neutral at pH 5.5/7.4. T1‐weighted images showed MCCS actively targeted tumors to improve the relaxation rate r1 and contrast time of MRI. This studies demonstrated MCCS raises reactive oxygen species levels, activates the cGAS‐STING pathway, stimulates effectors CD8+ and CD80+ T cells, reduces regulatory T cell numbers, and increases IFN‐γ and granzyme secretion, thereby inducing tumor cells autophagy and apoptosis in vitro and in vivo. Also, MCCS are biocompatible and biosafe. These studies show the great potential of Mn‐/SS‐based integrative material MCCS for precision and personalized tumor nanotheragnostics.
materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology